Steroid hormone transforming aldo-keto reductases and cancer.

Trevor M Penning, Michael C Byrns

Journal: Annals of the New York Academy of Sciences 2009;1155():33-42

PMID: 19250190

Free Full Text on PubMed Central View on PubMed

Abstract

Prostate and breast cancer are hormone-dependent malignancies of the aging male and female and require the local production of androgens and estrogens to stimulate cell proliferation. Aldo-keto reductases (AKR) play key roles in this process. In the prostate, AKR1C3 (type 5 17beta-HSD) reduces Delta(4)-androstene-3,17-dione to yield testosterone while AKR1C2 (type 3 3alpha-HSD) eliminates 5alpha-dihydrotestosterone (5alpha-DHT), and AKR1C1 forms 3beta-androstanediol (a ligand for ERbeta). In the breast, AKR1C3 forms testosterone, which is converted to 17beta-estradiol by aromatase or reduces estrone to 17beta-estradiol directly. AKR1C3 also acts as a prostaglandin (PG) F synthase and forms PGF(2alpha) and 11beta-PGF(2alpha), which stimulate the FP receptor and prevent the activation of PPARgamma by PGJ(2) ligands. This proproliferative signaling may stimulate the growth of hormone-dependent and -independent prostate and breast cancer.

Address: Center of Excellence in Environmental Toxicology, Department of Pharmacology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104-6084, USA. [email protected]

DOI: 10.1111/j.1749-6632.2009.03700.x

Link outs

Free resources

Full Text Sources:

Medical:

https://medlineplus.gov/prostatecancer.html

Research Materials:

https://antibodies.cancer.gov/detail/CPTC-AKR1C1-1

Subscription / membership required

Full Text Sources:

MeSH Terms: Alcohol Oxidoreductases, Aldehyde Reductase, Aldo-Keto Reductases, Androgens, Breast, Breast Neoplasms, Chromosome Mapping, Enzyme Inhibitors, Estrogens, Female, Humans, Hydroxyprostaglandin Dehydrogenases, Isoenzymes, Male, Prostate, Prostatic Neoplasms